A global biopharma company, inspired by the needs of people living with severe diseases
At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions. And thanks to our focused, innovative and trusted solutions, our business is strong, with total revenue reaching € 5.3 billion in 2023.
This success is powered by the approximately 9,000 people – from our headquarters in Belgium and across nearly 40 countries worldwide. Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve.
Our vision
UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life that they can – as free as possible from the challenges and uncertainty of disease. That commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition align with unmet needs.
UCB is continuously working to advance science and embrace new knowledge, bringing passion and leadership to solving the challenges that matter to people living with severe diseases. We are leveraging scientific advances and new technologies in areas including genetics, biomarkers and human biology. Continually inspired by those we serve to bring differentiated solutions with unique outcomes that deliver tangible, positive impacts.
Our strategy
We are intently and uniquely focused on delivering valuable solutions to people living with severe diseases. We do this by seeing the person behind the disease and by understanding that their needs go beyond just treatment.
This is why our work is rooted in a culture of dialogue, collaboration and respect, allowing us to forge bonds with the people we serve and those who know their challenges best, ensuring that our work can have the greatest possible impact.
We believe in partnership and seek out those who share our commitment to delivering valuable solutions. Whether that’s collaborating with leading researchers from academia or peers within our industry, we invest in meaningful partnerships to address the critical challenges we’re focused on solving.
Discover more about us
Our history
